KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBIT: 2010-2025

Historic EBIT for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -$178.0 million.

  • Novavax's EBIT fell 32.83% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 202.01%. This contributed to the annual value of -$248.9 million for FY2024, which is 56.06% up from last year.
  • Per Novavax's latest filing, its EBIT stood at -$178.0 million for Q3 2025, which was down 276.13% from $101.1 million recorded in Q2 2025.
  • Novavax's EBIT's 5-year high stood at $515.5 million during Q1 2025, with a 5-year trough of -$825.0 million in Q4 2021.
  • In the last 3 years, Novavax's EBIT had a median value of -$131.1 million in 2024 and averaged -$34.3 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 1,931.06% in 2021, then surged by 455.94% in 2025.
  • Novavax's EBIT (Quarterly) stood at -$825.0 million in 2021, then spiked by 70.44% to -$243.9 million in 2022, then grew by 24.73% to -$183.6 million in 2023, then rose by 28.59% to -$131.1 million in 2024, then slumped by 32.83% to -$178.0 million in 2025.
  • Its last three reported values are -$178.0 million in Q3 2025, $101.1 million for Q2 2025, and $515.5 million during Q1 2025.